Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Review
  • Published:

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders

Leukemia volume 22, pages 905–914 (2008)Cite this article

Abstract

Among the ‘classic’ BCR/ABL-negative chronic myeloproliferative disorders, primary myelofibrosis (PMF) is associated with a substantial life-expectancy reduction. In this disease, initial haemoglobin level is the most important prognostic factor, whereas age, constitutional symptoms, low or high leukocyte counts, blood blast cells and cytogenetic abnormalities are also of value. Several prognostic systems have been proposed to identify subgroups of patients with a different risk, which is especially important in younger individuals, who may benefit from therapies with curative potential. Essential thrombocythaemia (ET) affects the patients’ quality of life more than the survival, due to the high occurrence of thrombosis, whereas polycythaemia vera (PV) has a substantial morbidity derived from thrombosis but also a certain reduction in life expectancy. Therefore, in the latter disorders, prognostic studies have focused primarily on prediction of the thrombosis, with age and a previous history of thrombosis being the main prognostic factors of such complication. The importance of higher leukocyte counts in thrombosis development has been recently pointed out in ET and PV, where a role for mutated JAK2 allele burden has also been noted. With regard to PMF, the possible association of the mutation with shorter survival and higher acute transformation rate is currently being evaluated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.

    Article  CAS  Google Scholar 

  2. Kralowics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.

    Google Scholar 

  3. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005; 434: 1144–1148.

    Article  CAS  Google Scholar 

  4. Levine RL, Wadleigh M, Cools J, Eber BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.

    Article  CAS  Google Scholar 

  5. Dameshek W . Some speculations on the myeloproliferative syndrome. Blood 1951; 6: 372–375.

    CAS  Google Scholar 

  6. McNally RJ, Rowland D, Roman E, Cartwright RA . Age and sex distributions of hematological malignancies in the UK. Hematol Oncol 1997; 15: 173–189.

    CAS  Google Scholar 

  7. Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E . A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 1988; 70: 397–401.

    CAS  Google Scholar 

  8. Hasselbalch H . Idiopathic myelofibrosis. A clinical study of 80 patients. Am J Hematol 1990; 34: 291–300.

    CAS  Google Scholar 

  9. Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 1990; 75: 4–9.

    CAS  Google Scholar 

  10. Rupoli S, Da Lio L, Sisti S, Campanati G, Salvi A, Briamani MF et al. Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol 1994; 68: 205–212.

    CAS  Google Scholar 

  11. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018.

    CAS  Google Scholar 

  12. Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E . Identification of ‘short-lived’ and ‘long-lived’ patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997; 97: 635–640.

    CAS  Google Scholar 

  13. Reilly JT, Snowden JA, Spearing RL, Fitzgerald PM, Jones N, Watmore A et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 1997; 98: 96–102.

    CAS  Google Scholar 

  14. Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R . Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer 1997; 80: 708–719.

    CAS  Google Scholar 

  15. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT . Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67: 2658–2663.

    CAS  Google Scholar 

  16. Gruppo Italiano Studio Policitemia Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656–664.

    Google Scholar 

  17. Kiladjian JJ, Gardin C, Renoux M, Bruno F, Bernard JF . Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol J 2003; 4: 198–207.

    CAS  Google Scholar 

  18. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzani P, Valentini F et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117: 755–761.

    Google Scholar 

  19. Kutti J, Ridell B . Epidemiology of the myeloproliferative disorders: essential thrombocythemia, polycythemia vera and idiopathic myelofibrosis. Pathol Biol (Paris) 2001; 49: 164–166.

    CAS  Google Scholar 

  20. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A . Population based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study, 1975–1995. Am J Hematol 1991; 61: 10–15.

    Google Scholar 

  21. Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E . The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. Eur J Haematol 1998; 60: 101–105.

    CAS  Google Scholar 

  22. Morel P, Demory JL, Dupriez B . Relevance of prognostic features in myeloid metaplasia to selection of patients for bone marrow transplantation (letter). Blood 1997; 89: 2219–2220.

    CAS  Google Scholar 

  23. Cervantes F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998; 102: 684–690.

    CAS  Google Scholar 

  24. Elliott MA, Verstovsek S, Dingli D, Schawager SM, Mesa RA, Tefferi A . Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 2007; 31: 1503–1509.

    CAS  Google Scholar 

  25. Cervantes F, Barosi G, Hernández-Boluda JC, Marchetti M, Montserrat E . Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. Eur J Haematol 2001; 66: 324–327.

    CAS  Google Scholar 

  26. Altura R, Head DR, Wang WC . Long-term survival of infants with idiopathic myelofibrosis. Br J Haematol 2000; 109: 459–462.

    CAS  Google Scholar 

  27. Cervantes F, Alvarez-Larrán A, Talarn C, Gómez M, Montserrat E . Myelofibrosis with myeloid metaplasia following essential thrombocythemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 2002; 118: 786–790.

    Google Scholar 

  28. Najean Y, Dresch C, Rain JD . The very long-term course of polycythemia: a complement to the previously published data of the Polycythemia Vera Study Group. Br J Haematol 1994; 86: 233–235.

    CAS  Google Scholar 

  29. Passamonti F, Rumi E, Caranella M, Elena C, Arcaini L, Boveri E et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 2008 (e-pub ahead of print).

  30. Tefferi A, Huang J, Schwager S, Li CY, Wu W, Pardanani A et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis. Analysis based on 334 patients from a single institution. Cancer 2007; 109: 2083–2088.

    Google Scholar 

  31. Sagaster V, Jager E, Weltermann A, Schwarzinger I, Gisslinger H, Lecher K et al. Circulating hematopoietic progenitor cells predict survival in patients with myelofibrosis with myeloid metaplasia. Haematologica 2003; 88: 1204–1212.

    Google Scholar 

  32. Thiele J, Kvasnicka HM, Boeltken B, Zankovich R, Diehl V, Fischer R . Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF)—a clinicopathological study. Leukemia 1999; 13: 1741–1748.

    CAS  Google Scholar 

  33. Njoku OS, Lewis SM, Catovsky D, Gordon-Smith EC . Anaemia in myelofibrosis: its value in prognosis. Br J Haematol 1983; 54: 79–89.

    CAS  Google Scholar 

  34. Varki A, Lottenberg R, Griffith R, Reinhard E . The syndrome of idiopathic myelofibrosis: a clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine (Baltimore) 1983; 62: 353–371.

    CAS  Google Scholar 

  35. Tefferi A, Silverstein MN . Agnogenic myeloid metaplasia. Cancer Invest 1997; 15: 177–179.

    CAS  Google Scholar 

  36. Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A . Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer 2006; 106: 1985–1989.

    Google Scholar 

  37. Najean Y, Cacchione R, Castro-Malaspina H, Dresch C . Erythrokinetic studies in myelofibrosis: their significance for prognosis. Br J Haematol 1978; 40: 205–217.

    CAS  Google Scholar 

  38. Thiele J, Kvasnicka HM, Werden C, Zankovich R, Diehl V, Fischer R . Idiopathic primary osteo-myelofibrosis: a clinicopathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk Lymphoma 2003; 22: 303–317.

    Google Scholar 

  39. Pereira A, Cervantes F, Brugués R, Rozman C . Bone marrow histopathology in primary myelofibrosis: clinical and hematologic correlations and prognostic evaluation. Eur J Haematol 1990; 44: 94–98.

    Google Scholar 

  40. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A . Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000; 96: 3374–3380.

    CAS  Google Scholar 

  41. Demory JL, Dupriez B, Fenaux P, Lai JL, Beuscart R, Jouet JP et al. Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood 1988; 72: 855–859.

    CAS  Google Scholar 

  42. Miller JB, Testa JR, Lindgren V, Rowley JD . The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis. Cancer 1985; 55: 582–591.

    CAS  Google Scholar 

  43. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW . Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 113: 763–771.

    CAS  Google Scholar 

  44. Barosi G, Viarengo G, Pecci A, Rosti V, Piaggio G, Marchetti M et al. Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia. Blood 2001; 98: 3249–3255.

    CAS  Google Scholar 

  45. Arora B, Sirhan S, Hover JD, Mesa RA, Tefferi A . Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. Br J Haematol 2004; 128: 42–48.

    Google Scholar 

  46. Barosi G, Ambrosetti A, Centra A, Rosti V, Piaggio G, Marchetti M et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Blood 1998; 91: 3630–3636.

    CAS  Google Scholar 

  47. Tefferi A, Mesa RA, Nagorney DN, Schroeder G, Silverstein MN . Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000; 95: 2226–2233.

    CAS  Google Scholar 

  48. Ania BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton III LJ . Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935–1989. Am J Hematol 1994; 47: 89–93.

    CAS  Google Scholar 

  49. Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC . Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 2000; 65: 132–139.

    CAS  Google Scholar 

  50. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A . Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006; 81: 159–166.

    Google Scholar 

  51. Najean Y, Mugnier P, Dresch C, Rain JD . Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years. Br J Haematol 1987; 67: 285–291.

    CAS  Google Scholar 

  52. Passamonti F, Malabarba L, Orlandi E, Pascutto C, Brusamolino E, Astori C et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 2003; 88: 13–18.

    Google Scholar 

  53. Perea G, Remacha A, Besses C, Jiménez M, Florensa L, Cervantes F . Is polycythemia vera a serious disease in young adults? Haematologica 2001; 86: 543–544.

    CAS  Google Scholar 

  54. Passamonti F, Rumi E, Malabarba L, Arcaini L, Orlandi E, Brusamolino E et al. Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. Ann Hematol 2004; 83: 495–497.

    Google Scholar 

  55. Alvarez-Larrán A, Cervantes F, Bellosillo B, Giralt M, Juliá A, Hernández-Boluda JC et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia 2007; 21: 1218–1223.

    Google Scholar 

  56. Storen EC, Tefferi A . Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001; 97: 863–866.

    CAS  Google Scholar 

  57. Mazzucconi MG, Redi R, Bernasconi S, Bizzoni L, Dragoni F, Latagliata R et al. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica 2004; 89: 1306–1313.

    CAS  Google Scholar 

  58. Vardiman JW, Harris NL, Brunning RD . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302.

    CAS  Google Scholar 

  59. Thiele J, Kvasnicka HM . Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 2003; 82: 148–152.

    CAS  Google Scholar 

  60. Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL et al. Bone marrow pathology in essential thrombocythemia: inter-observer reliability and utility for identifying disease subtypes. Blood 2007; 111: 60–70.

    Google Scholar 

  61. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006; 107: 3676–3682.

    CAS  Google Scholar 

  62. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092–1097.

    CAS  Google Scholar 

  63. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23: 2224–2232.

    Google Scholar 

  64. Rumi E, Passamonti F, Della Porta MG, Elena C, Arcaini L, Vanelli L et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol 2007; 25: 5630–5635.

    Google Scholar 

  65. Elliott MA, Tefferi A . Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128: 275–290.

    CAS  Google Scholar 

  66. Passamonti F, Brusamolino E, Lazzarino M, Baratè C, Klersy C, Orlandi E et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica 2000; 85: 1011–1018.

    CAS  Google Scholar 

  67. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR . Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23: 132–143.

    CAS  Google Scholar 

  68. Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T . Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 8: 556–562.

    CAS  Google Scholar 

  69. Passamonti F, Malabarba L, Orlandi E, Pacutto C, Brusamolino E, Astori C et al. Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. Br J Haematol 2002; 116: 855–861.

    CAS  Google Scholar 

  70. Besses C, Cervantes F, Pereira A, Florensa L, Solé F, Hernández-Boluda JC et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999; 13: 150–154.

    CAS  Google Scholar 

  71. Bellucci S, Janvier M, Tobelem G, Flandrin G, Charpak Y, Berger R et al. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 1986; 58: 2440–2447.

    CAS  Google Scholar 

  72. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332: 1132–1136.

    CAS  Google Scholar 

  73. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33–45.

    CAS  Google Scholar 

  74. Michiels JJ . Acquired von Willebrand disease due to increasing platelet count can readily explain the paradox of thrombosis and bleeding in thrombocythemia. Clin Appl Thromb Hemost 1999; 5: 147–151.

    CAS  Google Scholar 

  75. Landolfi R, Di Gennaro L, Barbui T, de Stefano V, Finazzi G, Marfisi R et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007; 109: 2446–2452.

    CAS  Google Scholar 

  76. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007; 109: 2310–2313.

    CAS  Google Scholar 

  77. Tefferi A, Gangat N, Wolanskyj A . The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood 2007; 109: 4105.

    CAS  Google Scholar 

  78. Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96: 4261–4266.

    CAS  Google Scholar 

  79. Jensen MK, De Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch H . Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol 2001; 66: 143–151.

    CAS  Google Scholar 

  80. Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 2007; 35: 702–711.

    CAS  Google Scholar 

  81. Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Villamor N, Colomer D, Cervantes F . Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006; 91: 169–175.

    CAS  Google Scholar 

  82. Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Ruutu T . The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Ann Hematol 2001; 80: 74–78.

    CAS  Google Scholar 

  83. Shih LY, Lin TL, Lai CL, Dunn P, Wu JH, Wang PN et al. Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia. Blood 2002; 100: 1596–1601.

    CAS  Google Scholar 

  84. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F . Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549–556.

    CAS  Google Scholar 

  85. Finazzi G, Barbui T . How I treat patients with polycythemia vera. Blood 2007; 109: 5104–5111.

    CAS  Google Scholar 

  86. Barbui T, Finazzi G . When and how to treat essential thrombocythemia. N Engl J Med 2005; 353: 85–86.

    CAS  Google Scholar 

  87. Kiladjian JJ, Rain JD, Bernard JF, Brière J, Chomienne C, Fenaux P . Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006; 32: 417–421.

    CAS  Google Scholar 

  88. Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21: 270–276.

    CAS  Google Scholar 

  89. Finazzi G, Caruso V, Marchioli R, Capniat G, Chisesi T, Finelli C et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005; 105: 2664–2670.

    CAS  Google Scholar 

  90. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C et al. Efficacy ans safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114–124.

    CAS  Google Scholar 

  91. Najean Y, Rain JD . Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997; 90: 3370–3377.

    CAS  Google Scholar 

  92. Ruggeri M, Rodeghiero F, Tosetto A, Castamana G, Scognamiglio F, Finazzi G et al. Post-surgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 2007; 110: 666–671.

    Google Scholar 

  93. Griesshammer M, Struve S, Harrison CM . Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe. Semin Thromb Hemost 2006; 32: 422–429.

    Google Scholar 

  94. Heller PG, Lev PR, Salim JP, Kornblihtt LI, Goette NP, Chazarreta CD et al. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. Eur J Haematol 2006; 77: 210–216.

    CAS  Google Scholar 

  95. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C . The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 2006; 132: 244–245.

    CAS  Google Scholar 

  96. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847–1849.

    CAS  Google Scholar 

  97. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945–1953.

    CAS  Google Scholar 

  98. Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T . Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 2007; 92: 135–136.

    Google Scholar 

  99. Pemmaraju N, Moliterno AR, Williams DM, Rogers O, Spivak JL . The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Leukemia 2007; 21: 2210–2212.

    CAS  Google Scholar 

  100. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia 2007; 21: 1952–1959.

    CAS  Google Scholar 

  101. Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007; 109: 2279–2284.

    Google Scholar 

  102. Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008; 93: 41–48.

    CAS  Google Scholar 

  103. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 110: 840–846.

    CAS  Google Scholar 

  104. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006; 106: 631–635.

    CAS  Google Scholar 

  105. Tefferi A, Strand JJ, Lasho TL, Knudson RA, Finke CM, Gangat N et al. Bone marrow JAK2 V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007; 21: 2074–2076.

    CAS  Google Scholar 

  106. Maugeri N, Giordano G, Petrilli MP, Fraticelli V, de Gaetano G, Cerletti C et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost 2006; 4: 2593–2598.

    CAS  Google Scholar 

  107. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL . JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108: 1652–1660.

    CAS  Google Scholar 

  108. Tefferi A, Lasho TL, Schwager SM, Stennsma DP, Mesa RA, Li CY et al. The JAK2 V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 2005; 131: 320–328.

    CAS  Google Scholar 

  109. Campbell PJ, Griesshammer M, Döhner K, Döhner H, Kusec R, Hasselbalch HC et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006; 107: 2098–2100.

    CAS  Google Scholar 

  110. Rossi D, Deambrogi C, Capello D, Cerri M, Lunghi M, Parvis G et al. JAK2 V617F mutation in leukaemic transformation of Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol 2006; 135: 267–268.

    CAS  Google Scholar 

  111. Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E et al. Leukemic blasts in transformed JAK2-V617F positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007; 110: 375–379.

    CAS  Google Scholar 

  112. Mesa RA, Powell H, Lasho T, Dewald G, McClure R, Tefferi A . JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leuk Res 2006; 30: 1457–1460.

    CAS  Google Scholar 

  113. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007; 110: 430–436.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology Department, Hospital Cl,

    F Cervantes

  2. í,

    F Cervantes

  3. nic, IDIBAPS, University of Barcelona, Barcelona, Spain

    F Cervantes

  4. Hematology Department, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy

    F Passamonti

  5. Unit of Clinical Epidemiology, Center for the Study of Myelofibrosis, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy

    G Barosi

Authors
  1. F Cervantes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Passamonti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Barosi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F Cervantes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cervantes, F., Passamonti, F. & Barosi, G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 22, 905–914 (2008). https://doi.org/10.1038/leu.2008.72

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.72

Keywords

This article is cited by

Search

Advanced search

Quick links